NCT03729596: MGC018 With or Without MGA012 in Advanced Solid Tumors

NCT03729596
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PD-L1, B7-H3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors with B7-H3 & PD-L1 expression
Exclusions: Patients with symptomatic, untreated, unstable central nervous system (CNS) metastases and/or leptomenigeal disease that requires treatment – see trial for details; Patients with prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents for cancer
https://ClinicalTrials.gov/show/NCT03729596

Comments are closed.

Up ↑